Hepatitis Monthly

Published by: Kowsar

Metabolic Syndrome and Genotype 1 Virus C Compensated Liver Cirrhosis in the Era of Directly Acting Antiviral Therapy

Catalina Mihai 1 , 2 , Bogdan Mihai 1 , 3 , * , Anca Trifan 1 , 2 , Carol Stanciu 1 , 2 , Liana Gheorghe 4 , Mircea Diculescu 4 , Manuela Curescu 5 , Ciprian Brisc 6 , Adrian Goldis 7 , Simona Bataga 8 , Larisa Sandulescu 9 , Ion Rogoveanu 9 , Andrada Seicean 10 and Cristina Cijevschi Prelipcean 1 , 2
Authors Information
1 University of Medicine and Pharmacy “Grigore T. Popa”, Iasi, Romania
2 Institute of Gastroenterology and Hepatology, “St. Spiridon” Emergency Hospital, Iasi, Romania
3 Center of Diabetes, Nutrition and Metabolic Diseases, “St. Spiridon” Emergency Hospital, Iasi, Romania
4 Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania
5 University Hospital Infectious Diseases, Timisoara, Romania
6 Clinic of Gastroenterology and Hepatology, Oradea, Romania
7 Center Gastroenterology and Hepatology, University of Medicine and Pharmacy, Timisoara, Romania
8 Center of Gastroenterology, University of Medicine and Pharmacy, Tirgu Mures, Romania
9 Clinic of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Craiova, Romania
10 “Prof. dr. Octavian Fodor” Regional Institute of Gastroenterology and Hepatology, ClujNapoca, Romania
Article information
  • Hepatitis Monthly: July 2017, 17 (7); e58022
  • Published Online: July 16, 2017
  • Article Type: Research Article
  • Received: March 19, 2017
  • Accepted: July 1, 2017
  • DOI: 10.5812/hepatmon.58022

To Cite: Mihai C, Mihai B, Trifan A, Stanciu C, Gheorghe L, et al. Metabolic Syndrome and Genotype 1 Virus C Compensated Liver Cirrhosis in the Era of Directly Acting Antiviral Therapy, Hepat Mon. 2017 ; 17(7):e58022. doi: 10.5812/hepatmon.58022.

Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Negro F. HCV infection and metabolic syndrome: which is the chicken and which is the egg? Gastroenterology. 2012; 142(6): 1288-92[DOI][PubMed]
  • 2. Cheng YL, Wang YC, Lan KH, Huo TI, Huang YH, Su CW, et al. Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Ann Hepatol. 2015; 14(2): 181-9[PubMed]
  • 3. Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol. 2014; 20(23): 7089-103[DOI][PubMed]
  • 4. Kralj D, Virovic Jukic L, Stojsavljevic S, Duvnjak M, Smolic M, Curcic IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol. 2016; 4(1): 66-75[DOI][PubMed]
  • 5. Afzal MS, Zaidi NU, Dubuisson J, Rouille Y. Hepatitis C virus capsid protein and intracellular lipids interplay and its association with hepatic steatosis. Hepat Mon. 2014; 14(8)[DOI][PubMed]
  • 6. Wong RJ, Gish RG. Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2016; 12(5): 293-9[PubMed]
  • 7. Rafi H, Kabbaj N, Salihoun M, Amrani L, Acharki M, Guedira M, et al. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases. Arab J Gastroenterol. 2011; 12(3): 136-8[DOI][PubMed]
  • 8. Lim T. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? Hepat Med. 2014; 6: 113-8[DOI][PubMed]
  • 9. Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut. 2010; 59(12): 1694-8[DOI][PubMed]
  • 10. van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernandez-Rodriguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017; 66(3): 485-93[DOI][PubMed]
  • 11. Alberti KG, Zimmet P, Shaw J, I. D. F. Epidemiology Task Force Consensus Group . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491): 1059-62[DOI][PubMed]
  • 12. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ. 2006; 332(7546): 878-82[DOI][PubMed]
  • 13. Popa S, Mota M, Popa A, Mota E, Serafinceanu C, Guja C, et al. Prevalence of overweight/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study. J Endocrinol Invest. 2016; 39(9): 1045-53[DOI][PubMed]
  • 14. Serste T, Nkuize M, Moucari R, Van Gossum M, Reynders M, Scheen R, et al. Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity. Liver Int. 2010; 30(8): 1131-6[DOI][PubMed]
  • 15. Banks DE, Bogler Y, Bhuket T, Liu B, Wong RJ. Significant disparities in risks of diabetes mellitus and metabolic syndrome among chronic hepatitis C virus patients in the U.S. Diabetes Metab Syndr. 2016; [DOI][PubMed]
  • 16. Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016; 17(6)[DOI][PubMed]
  • 17. Lonardo A, Ballestri S, Adinolfi LE, Violi E, Carulli L, Lombardini S, et al. Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol. 2009; 23(4): 273-8[PubMed]
  • 18. Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016; 17(3): 355[DOI][PubMed]
  • 19. Mota M, Popa SG, Mota E, Mitrea A, Catrinoiu D, Cheta DM, et al. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. J Diabetes. 2016; 8(3): 336-44[DOI][PubMed]
  • 20. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994; 21(6): 1135-9[PubMed]
  • 21. Safi SZ, Shah H, Siok Yan GO, Qvist R. Insulin resistance provides the connection between hepatitis C virus and diabetes. Hepat Mon. 2015; 15(1)[DOI][PubMed]
  • 22. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. 2016; 150(7): 1599-608[DOI][PubMed]
  • 23. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, Diago M, Alonso S, Planas R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008; 48(5): 721-7[DOI][PubMed]
  • 24. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology. 2006; 44(2): 335-40[DOI][PubMed]
  • 25. Zhu YZ, Qian XJ, Zhao P, Qi ZT. How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol. 2014; 20(13): 3457-67[DOI][PubMed]
  • 26. Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016; 22(44): 9674-93[DOI][PubMed]
  • 27. Yair-Sabag S, Nussinson E, Ben-Assuli O, Shibli F, Shahbari A, Zelber-Sagi S. Retrospective study of the associations between hepatitis C virus infection and metabolic factors. World J Hepatol. 2016; 8(30): 1269-78[DOI][PubMed]
  • 28. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol. 2010; 8(5): 458-62[DOI][PubMed]
  • 29. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2012; 61(1): 128-34[DOI][PubMed]
  • 30. Zhang W, Rao HY, Feng B, Liu F, Wei L. Effects of interferon-alpha treatment on the incidence of hyperglycemia in chronic hepatitis C patients: a systematic review and meta-analysis. PLoS One. 2012; 7(6)[DOI][PubMed]
  • 31. Pavone P, Tieghi T, d'Ettorre G, Lichtner M, Marocco R, Mezzaroma I, et al. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016; 22(5): 462 e1-3[DOI][PubMed]
  • 32. Fernandez-Rodriguez CM, Lopez-Serrano P, Alonso S, Gutierrez ML, Lledo JL, Perez-Calle JL, et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther. 2006; 24(3): 507-12[DOI][PubMed]
  • 33. Kuo YH, Chuang TW, Hung CH, Chen CH, Wang JH, Hu TH, et al. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. J Formos Med Assoc. 2011; 110(6): 363-71[DOI][PubMed]
  • 34. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol. 2006; 12(42): 6756-65[PubMed]
  • 35. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015; 61(3): 790-801[DOI][PubMed]
  • 36. Huang YW, Yang SS, Fu SC, Wang TC, Hsu CK, Chen DS, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology. 2014; 60(3): 807-14[DOI][PubMed]
  • 37. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016; 64(1): 130-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments